Shilpa Antibiotics Ltd was incorporated as a Private Limited Company
 in November 1987.  The commercial production of the Company had
 started in November 1989. The Company was initially producing
 Trimethoprim IP/BP, an antibiotic bulk drug.  The technology for the
 bulk drug was developed in house.  During the first year of its
 operation the Company had installed production facilities to
 manufacture Trimethoprim Apart from selling on its own, the Company
 had also started manufacturing the product for other reputed
 Companies like Eskayef Limited, Bombay Drugs
 and Pharmas Limited, Bombay Drug House Ltd., US Vitamins Ltd, Sandoz
 India Ltd etc for their export commitments.
 
 During 1992, the Company had installed production facilities for
 manufacture of Sodium Methoxide.  The technology for the same had
 also been developed in house. During the same year the Company
 secured Export orders from Stellar Exports Limited, Glaxo Limited and
 Deepak Nitrite
 Limited for Trimethoprim.  Since then the company has started
 exporting on its own.  The Company thus started manufacturing for
 both export and domestic markets since 1992.  It has obtained World
 Health Organisation-Good Manufacturing Practices (GMP) Certificate. 
 It has also been exporting its products to hard currency areas.
 
 The Company now proposes to embark upon an expansion project which
 involves the addition of one more bulk drug to its existing product
 range viz; Norfloxcin and expansion of the production capacity of the
 existing product of the Company viz; Sodium Methoxide and
 Trimethoprim.  The Company also proposes to manufacture 1-Methyl
 Amino-1-Methyl Thio-2-Nitro Ethane, a drug intermediate, used in the
 manufacture of Ranitidine, an anti-ulcer drug. To raise the necessary
 resources to finance the expansion project of the Company, the Company
 was converted into a Public Limited Company in November 1993.
 
 As the company's sales are comparatively more in the September to
 March period, therefore, to reduce the administrative bottlenecks in
 the timely preparation of annual results, the company changed its
 accounting year from March end to September end.
 
 Objects of the Company
 
 The relevant objects of the company as set out in the memorandum of
 association of the company are :
 
 Main Objects
 
 1. To carry on in India or elsewhere the industry, trade or business
 of manufacturers, Traders, Dealers, Agents, Suppliers, Licensors,
 Licensees, Loan Licenses, Importers, Exporters, Consultants,
 Discoverers, Inventors, and Producers of Drugs, Bulk Drugs,
 Pharmaceuticals, Pharmaceutical Formulations, Alcohol, Bended
 Laboratory
 Preparations, and general medicinal preparation and or their
 by-products and packing and re-packing of the above.
 
 
 2007
 
 -Shilpa Medicare Ltd has entered into a memorandum of understanding
 (MoU) with LOBA Finchemie AG, Austria, to acquire 100% shares of LOBA
 in an all-cash deal.
 
 - The Company has splits its face value from Rs10/- to Rs2/-.
 
 2008
 
 -Shilpa Medicare Ltd has informed that the Board of Director of the
 Company has co-opted Mr. Sunki Rajendra reddy S/o. Mr Rajeshwara
 Reddy as an Additional Director.
 
 -Shilpa Medicare Ltd has informed that the Board of Directors of the
 Company has co-opted Mr. N P S Shinh S/o. Mr. S Prithipal Singh Shinh
 as an Additional Director.
 
 2009
 
 - Shilpa Medicare Ltd has informed that the Company has signed a MOU
 to form a joint venture company to manufacture drugs and
 pharmaceuticals with ICE S.r.l. and PCA S.p.a. of Italy.